CHARLES SCHWAB INVESTMENT MANAGEMENT INC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$428,594
-16.3%
363,2150.0%0.00%
Q2 2023$512,133
+400.7%
363,215
+432.7%
0.00%
Q1 2023$102,275
+91.9%
68,183
+49.7%
0.00%
Q4 2022$53,288
+2.5%
45,5450.0%0.00%
Q3 2022$52,000
-27.8%
45,5450.0%0.00%
Q2 2022$72,000
-85.9%
45,545
-86.3%
0.00%
Q1 2022$512,000
-33.8%
332,406
+5.4%
0.00%
Q4 2021$773,000
-2.8%
315,3540.0%0.00%
Q3 2021$795,000
-13.5%
315,354
-2.2%
0.00%
Q2 2021$919,000
+706.1%
322,361
+569.3%
0.00%
Q1 2021$114,000
-2.6%
48,167
-27.2%
0.00%
Q4 2020$117,000
+88.7%
66,1800.0%0.00%
Q3 2020$62,000
+6.9%
66,1800.0%0.00%
Q2 2020$58,000
-70.1%
66,180
-71.7%
0.00%
Q1 2020$194,000
-6.7%
233,6870.0%0.00%
Q4 2019$208,000
-9.6%
233,6870.0%0.00%
Q3 2019$230,000233,6870.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2020
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders